Trucode: advancing nuclease-free, viral vector-independent gene therapy
A nuclease-free gene editing technology out of Yale finds a new home in Trucode
After bouncing around in several different companies, Peter Glazer’s peptide nucleic acid gene editing technology is getting another shot at development with the launch of Trucode.
This time around, the technology is more advanced and is entering a gene editing industry that is gradually becoming more de-risked as gene therapies hit the market and gene editing therapies enter the clinic.
Trucode Gene Repair Inc. emerged from stealth on Tuesday with a $34 million initial investment from Kleiner Perkins,